Shares of Epizyme Inc. (NASDAQ:EPZM) fell 1.6% during trading on Monday . The company traded as low as $7.42 and last traded at $7.58, with a volume of 147,232 shares trading hands. The stock had previously closed at $7.70.

A number of research firms recently commented on EPZM. Zacks Investment Research cut shares of Epizyme from a “buy” rating to a “hold” rating in a research report on Thursday, May 5th. Wedbush restated an “outperform” rating and issued a $22.00 price objective on shares of Epizyme in a research report on Monday, May 9th. Mizuho lowered their price objective on shares of Epizyme from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, May 10th. HC Wainwright restated a “buy” rating on shares of Epizyme in a research report on Tuesday, May 10th. Finally, JMP Securities restated a “buy” rating and issued a $28.00 price objective on shares of Epizyme in a research report on Thursday, June 23rd. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $23.11.

The stock has a 50-day moving average price of $9.21 and a 200-day moving average price of $10.35. The stock’s market capitalization is $423.08 million.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.03. On average, equities analysts forecast that Epizyme Inc. will post ($2.19) earnings per share for the current year.

In other news, insider Robert A. Copeland sold 4,000 shares of Epizyme stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $10.03, for a total transaction of $40,120.00. Following the transaction, the insider now owns 4,000 shares in the company, valued at $40,120. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

An institutional investor recently raised its position in Epizyme stock. Jennison Associates LLC raised its position in Epizyme Inc. (NASDAQ:EPZM) by 252.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 893,913 shares of the biopharmaceutical company’s stock after buying an additional 640,245 shares during the period. Jennison Associates LLC owned about 2.14% of Epizyme worth $14,320,000 at the end of the most recent reporting period.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.